drugset / Trial / NCT01843647
Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the overall response rate and disease free survival for IIIAN2 non-small-cell lung cancer patients with EGFR 19 or 21 exon mutation.
Timeline
- Start
- 2013-04
- Primary completion
- 2016-12
- Completion
- 2018-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cisplatin | Other / unclassified | — | — |
| Subject | Icotinib | Small molecule | 125 mg | Oral |
| Comparator | Vinorelbine | Small molecule | — | — |